Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.
OsteOpOrOsis
Definition of Osteoporosis: A condition of skeletal fragility characterized by:• Low bone mass. • Low bone quality        ...
Normal Bone   Osteoporosis
PREVALENCE• At age of 50 years: risk of hip fracture is:  – 15% of white woman.  – 5% of men.• At age of 80 years: risk of...
Types of osteoporosis(1) Involutional, or primary, osteoporosis, in which no    underlying cause can be identified.(2) Sec...
Pathogenesis1- Genetic factors:   Polygenic.The single most significant   influence on peak bone mass.2- Nutritional facto...
Risk factors• Endogenous factors:   – Female gender.   – Advancing age.   – Family history of fracture.• Exogenous factors...
Risk factors• Endocrine disorders:  – Cushings syndrome.  – Hyperparathyroidism.  – Thyrotoxicosis.  – Insulin-dependent d...
• Hematologic disorders/malignancy :  –   Multiple myeloma.  –   Lymphoma and Leukemia.  –   Hemophilia.  –   Thalassemia....
Symptoms• Osteoporosis, the "silent disease," has bone loss  without symptoms.• Onset only occurs with sudden strains, or ...
Diagnosis• Diagnosis is usually made following low  trauma fragility fracture as Colle’s , Vertebral,  Hip, Proximal humer...
Who Should Be Tested?• All women aged 65 and older.*• Younger postmenopausal women with multiple risk factors.• Postmenopa...
Bone Densitometry
DEXA scan: Hip    T-Score
WHO proposal for diagnosis of white  postmenopausal osteoporosis• >-1       SD           -Normal• -1 to -2.5 SD      -Low ...
Other Bone Density Measurements• Quantitative CT scanning :   – Distinction between trabecular and cortical bone.   – More...
Bone Markers• Alkaline phosphatase is derived from liver,  bone, kidney (and placenta). Bone-specific  alkaline phosphatas...
How can we exclude an underlying                cause ?•   CBC.•   ESR.•   Biochemistry.•   RFT.•   LFT: Alk phosphatase, ...
IN SPECIFIC SITUATION• Estradiol – FSH if hormonal state is  unclear as posthystrectomy.• Serum and urine electrophoresis....
Treatment
PreventionCalcium and Vitamin D Intake• 400-800 Units per day.
Prevention
Lifestyle modification• Weight bearing exercise:  Jumping ↑ bone mass and walking ↓ fracture risk.• Prevent falls: Esp for...
Weight-Bearing Exercise Consult your doctor first
Therapeutic Agents Used in Osteoporosis• Inhibitors of bone          • Stimulators of bone formation:  resorption:        ...
1- Ca 1200 mg/day for postmenopausal:• Pure ca carbonate (taken with food).• Pure ca citrate ( taken ± food).2- Vitamin D:...
Bisphosphonates 1. Alendronate and alendronate plus vitamin D    (brand name Fosamax® and Fosamax® plus D). 2. Ibandronate...
Bisphosphonates:Dose:  Prevention: 5 mg/d or 35 mg/w.  ttt : 10 mg/d or 70 mg/w.. Oral BPNs alendronate (Fosamax),  risedr...
Combination TherapyCombination therapy with two antiresorptiveagents is generally reserved for those who:  • Have experien...
1Rank[d],DALL            Postmenopausal cases
Estrogen / Hormone Therapy1. Estrogens (brand names, such as Climara®, Premarin®)2. Estrogens and Progestins (brand names,...
Selective estrogen receptor modulator (SERM) Raloxifene (Evista)ACT on bone receptors and not breast or uterus receptors• ...
Calcitonin• Salmon calcitonin is a synthetic polypeptide that  duplicates the molecular structure of calcitonin found in  ...
PTH: TeriparatideDose: 20 ug/d SC.• Intermittent exposure to PTH can  enhance bone mass.65% ↓ Vertebral fracture.• 53% ↓ ...
Surgical Treatment• Appropriate treatment of fragility fractures.• Hip nailing.• Kyphoplasty – Vertebroplasty.
How can you MONITOR ttt• Max improvement occurs in 1st year.• Monitor BMD every 2 years.• Response to strong antiresorptiv...
Osteoporosis
Prochain SlideShare
Chargement dans…5
×

Osteoporosis

10 162 vues

Publié le

  • Identifiez-vous pour voir les commentaires

Osteoporosis

  1. 1. OsteOpOrOsis
  2. 2. Definition of Osteoporosis: A condition of skeletal fragility characterized by:• Low bone mass. • Low bone quality (trabecular micro- architecture).• ↑bone fragility predisposing to an increased risk of fracture.
  3. 3. Normal Bone Osteoporosis
  4. 4. PREVALENCE• At age of 50 years: risk of hip fracture is: – 15% of white woman. – 5% of men.• At age of 80 years: risk of hip fracture is: – 30% of women. – 15% of men.
  5. 5. Types of osteoporosis(1) Involutional, or primary, osteoporosis, in which no underlying cause can be identified.(2) Secondary osteoporosis, in which the underlying cause (eg, steroid use) is known.(3) Rare forms of the disease, such as juvenile, pregnancy- related, and postpartum osteoporosis.
  6. 6. Pathogenesis1- Genetic factors: Polygenic.The single most significant influence on peak bone mass.2- Nutritional factors.3- Sex hormone status.4- Physical activity.
  7. 7. Risk factors• Endogenous factors: – Female gender. – Advancing age. – Family history of fracture.• Exogenous factors: – Hypogonadism (male or female). – Glucocorticoid treatment. – Low body mass index. – Previous fracture. – Smoking. – Immobilization. – Excess alcohol. – Vitamin D and calcium deficiencies in the elderly.
  8. 8. Risk factors• Endocrine disorders: – Cushings syndrome. – Hyperparathyroidism. – Thyrotoxicosis. – Insulin-dependent diabetes mellitus. – Acromegaly. – Adrenal insufficiency.• Rheumatologic disorders: – Rheumatoid arthritis. – Ankylosing spondylitis.
  9. 9. • Hematologic disorders/malignancy : – Multiple myeloma. – Lymphoma and Leukemia. – Hemophilia. – Thalassemia.• Nutritional and gastrointestinal disorders: – Malnutrition. – Parenteral nutrition. – Malabsorption syndromes. – Inflammatory bowel diseases. – Gastrectomy. – Severe liver or renal disease (especially biliary cirrhosis). – Pernicious anemia.
  10. 10. Symptoms• Osteoporosis, the "silent disease," has bone loss without symptoms.• Onset only occurs with sudden strains, or fall causes a fracture or a vertebra to collapse.• Collapsed vertebrae may initially be felt or seen in the form of severe back pain, loss of height, or spinal deformities such as kyphosis or stooped posture.• Dowager’s hump (kyphosis + loss of height + cervical lordosis) present in severe cases.• Peripheral fractures are more common in osteoporosis than hip and spine.
  11. 11. Diagnosis• Diagnosis is usually made following low trauma fragility fracture as Colle’s , Vertebral, Hip, Proximal humerus, Rib, and Pelvic fractures.• QCT: The best for trabecular bones. High radiation dose & cost.• The gold standard is DEXA: – Hip ± Spine (trabecular). – Forearm in hyperpara. (cortical).
  12. 12. Who Should Be Tested?• All women aged 65 and older.*• Younger postmenopausal women with multiple risk factors.• Postmenopausal women who present with fractures.• Estrogen deficient women at clinical risk for osteoporosis.• Individuals with vertebral abnormalities.• Individuals receiving, or planning to receive, long-term glucocorticoid (steroid) therapy > 7 mg for > 3m.• Individuals with primary hyperparathyroidism.• Essential before ttt of osteoporosis to assess the response or efficacy of an approved osteoporosis drug therapy.
  13. 13. Bone Densitometry
  14. 14. DEXA scan: Hip T-Score
  15. 15. WHO proposal for diagnosis of white postmenopausal osteoporosis• >-1 SD -Normal• -1 to -2.5 SD -Low bone mass• <-2.5 SD -Osteoporosis• <-2.5 SD -Established+ fragility fracture severe osteopoT-score: SD of young adult peak mean value.-1SD = 10% bone loss
  16. 16. Other Bone Density Measurements• Quantitative CT scanning : – Distinction between trabecular and cortical bone. – More expensive. – Higher radiation than other techniques.• Quantitative ultrasound of the calcaneum: – Difficulties - Limited in routine use.• Bone biopsy: – Bone biopsy may be useful in unusual forms of osteoporosis, such as osteoporosis in young adults. – Biopsy provides information about the rate of bone turnover and the presence of secondary forms of osteoporosis, such as myeloma and systemic mastocytosis.
  17. 17. Bone Markers• Alkaline phosphatase is derived from liver, bone, kidney (and placenta). Bone-specific alkaline phosphatase is synthesized by osteoblasts; serum levels are raised in the growing child.• Serum osteocalcin levels.• Pyridinoline or deoxypyridinoline are produced by collagen degradation, and excreted in urine. Deoxypyridinoline is bone-specific, and both are more sensitive than urinary hydroxyproline.
  18. 18. How can we exclude an underlying cause ?• CBC.• ESR.• Biochemistry.• RFT.• LFT: Alk phosphatase, Alb, AST, ϒ GT.• Ca, p, Alk ph.• TFT: TSH• Testosterone – LH (in men).
  19. 19. IN SPECIFIC SITUATION• Estradiol – FSH if hormonal state is unclear as posthystrectomy.• Serum and urine electrophoresis.• Isotopic bone scan.
  20. 20. Treatment
  21. 21. PreventionCalcium and Vitamin D Intake• 400-800 Units per day.
  22. 22. Prevention
  23. 23. Lifestyle modification• Weight bearing exercise: Jumping ↑ bone mass and walking ↓ fracture risk.• Prevent falls: Esp for hip fracture: – Fall-proofing the houeshold. – Avoid drugs with dizziness & postural hypotension. – Hip protectors.• Diet: balanced diet.• Vitamin B5 (Pantothenic acid) reduces bone loss.• Vitamin K is required for osteocalcin to function properly.• Avoid alcohol, smoking and caffeine.• Avoid high amounts of calcium and Vitamin A.• Avoid high sodium retention negatively affects calcium / magnesium.• Avoid long-term use of Aspirin or NSAIDs, reduce magnesium and calcium.
  24. 24. Weight-Bearing Exercise Consult your doctor first
  25. 25. Therapeutic Agents Used in Osteoporosis• Inhibitors of bone • Stimulators of bone formation: resorption: – PTH. – Calcium . – Fluoride. – Estrogens +/- progest. – SERMs. – Bisphosphonates – Calcitonin.
  26. 26. 1- Ca 1200 mg/day for postmenopausal:• Pure ca carbonate (taken with food).• Pure ca citrate ( taken ± food).2- Vitamin D: 400 for adults -800 for elderly adults IU/D ( multivitamin).Pitfall : Calcitriol should not be given regularly Risk for hypercalcemia. Need plasma Ca monitor/3 m.
  27. 27. Bisphosphonates 1. Alendronate and alendronate plus vitamin D (brand name Fosamax® and Fosamax® plus D). 2. Ibandronate (brand name Boniva®). 3. Risedronate and risedronate with calcium (brand name Actonel® and Actonel® with Calcium). 4. Calcitonin (brand name Miacalcin®).Indications:  Steroid induced osteoporosis  Men osteoporosis .  Prevention and treatment of osteoporosis.Effect: Anti-fracture effect: inhibit osteoclast function and decrease bone turnover
  28. 28. Bisphosphonates:Dose: Prevention: 5 mg/d or 35 mg/w. ttt : 10 mg/d or 70 mg/w.. Oral BPNs alendronate (Fosamax), risedronate (Actonel) have poor absorption rates and must be taken on an empty stomach with water.
  29. 29. Combination TherapyCombination therapy with two antiresorptiveagents is generally reserved for those who: • Have experienced a fracture while on therapy with a single drug. • Start out with a very low BMD and a history of multiple fractures. • Have a very low BMD and lose more bone mass on therapy with a single drug.
  30. 30. 1Rank[d],DALL Postmenopausal cases
  31. 31. Estrogen / Hormone Therapy1. Estrogens (brand names, such as Climara®, Premarin®)2. Estrogens and Progestins (brand names, such as Premphase®, Prempro®.3. Parathyroid Hormone – Teriparatide (PTH (1-34) (brand name Fortéo®)
  32. 32. Selective estrogen receptor modulator (SERM) Raloxifene (Evista)ACT on bone receptors and not breast or uterus receptors• Indications for prevention and treatment.• 60 mg/d. 40% ↑BMD. 50% ↓ hip-spine fractures after 3 ys.• Risk: – Menopausal symptoms : HOT FLUSH. – DVT & PE. – ?? CVD.
  33. 33. Calcitonin• Salmon calcitonin is a synthetic polypeptide that duplicates the molecular structure of calcitonin found in the salmon fish.• Salmon calcitonin is more potent than human calcitonin.• Nasal spray (Miacalcin) is the most convenient form.• approved by the FDA for treatment of postmenopausal osteoporosis. Calcitonin inhibits osteoclast-induced bone resorption.• Limited uses: Expense.• SE: allergy: salmon.• Strong analgesic.
  34. 34. PTH: TeriparatideDose: 20 ug/d SC.• Intermittent exposure to PTH can enhance bone mass.65% ↓ Vertebral fracture.• 53% ↓ Non-vertebral fracture.• increased vertebral, femoral, and total-body BMD.
  35. 35. Surgical Treatment• Appropriate treatment of fragility fractures.• Hip nailing.• Kyphoplasty – Vertebroplasty.
  36. 36. How can you MONITOR ttt• Max improvement occurs in 1st year.• Monitor BMD every 2 years.• Response to strong antiresorptive agents effect is best seen in the spine.• EFFECTIVE TTT IF 5% RISE AT SPINE.• Use of biochemical markers: – Formation: Alk Ph – osteocalcin. – Resorption: N- telopeptide.

×